Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease

References

• Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:390–407.
   PubMedGoogle Scholar
• Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008;14:390–400.
   PubMed Web of Science ®Google Scholar
• van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443–8.
   PubMed Web of Science ®Google Scholar
• Strober W, Zhang F, Kitani A, Fuss I, Fichtner-Feigl S. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol 2010;26:310–17.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–33.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232–9.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106:S2–25.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van AG, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102–11.
   PubMed Web of Science ®Google Scholar
• Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22–8.
   PubMed Web of Science ®Google Scholar
• D'Haens G, Noman M, Baert F, Hiele MI. Endoscopic healing after infliximab treatment for Crohn's disease provides longer time to relapse. Gastroenterology 2002;122.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. J Crohn's Colitis 2011;5:477–83.
   Google Scholar
• Daperno M, Castiglione F, de Ridder L, Dotan I, Farkkila M, Florholmen J, Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011;5:484–98.
   PubMed Web of Science ®Google Scholar
• Daperno M, D'Haens G, Van AG, Baert F, Bulois P, Maunoury V, Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505–12.
   PubMed Web of Science ®Google Scholar
• Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011;34:911–22.
   PubMed Web of Science ®Google Scholar
• Fuss IJ. Is the Th1/Th2 paradigm of immune regulation applicable to IBD? Inflamm Bowel Dis 2008;14:S110–12.
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65–70.
   PubMed Web of Science ®Google Scholar
• Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011;56:633–40.
   PubMed Web of Science ®Google Scholar
• Li Z, Arijs I, De Hertogh G, Vermeire S, Noman M, Bullens D, Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010;16:1299–310.
   PubMed Web of Science ®Google Scholar
• Liu Z, Jiu J, Liu S, Fa X, Li F, Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. J Autoimmun 2007;29:187–94.
   PubMed Web of Science ®Google Scholar
• Rismo R, Olsen T, Ciu G, Paulssen EJ, Christiansen I, Florholmen J, The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease. Scand J Gastroenterol 2012;47:1200–10.
   PubMed Web of Science ®Google Scholar
• Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, IL–23/IL–17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis 2008;14:1175–84.
   PubMed Web of Science ®Google Scholar
• Arijs I, Quintens R, Van LL, Van SK, De HG, Lemaire K, Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010;16:2090–8.
   PubMed Web of Science ®Google Scholar
• Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol 2012;47:538–47.
   PubMed Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63–70.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Thomsen OO, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012;47:518–27.
   PubMed Web of Science ®Google Scholar
• Waugh AW, Garg S, Matic K, Gramlich L, Wong C, Sadowski DC, Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010;32:1129–34.
   PubMed Web of Science ®Google Scholar
• Molnar T, Farkas K, Miheller P, Nyari T, Szepes Z, Herszenyi L, Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease? J Crohns Colitis 2008;2:322–6.
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199–212.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402–13.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004;126:1518–32.
   PubMed Web of Science ®Google Scholar
• Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand J Clin Lab Invest 2006;66:249–59.
   PubMed Web of Science ®Google Scholar
• Goll R, Olsen T, Cui G, Florholmen J. Evaluation of absolute quantitation by nonlinear regression in probe-based real-time PCR. BMC Bioinformatics 2006;7:107.
   PubMed Web of Science ®Google Scholar
• Goll R, Gruber F, Olsen T, Cui G, Raschpichler G, Buset M, Helicobacter pylori stimulates a mixed adaptive immune response with a strong T-regulatory component in human gastric mucosa. Helicobacter 2007;12:185–92.
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101–8.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Infliximab (review) and Adalimumab for the treatment of Crohn's disease. NICE technology appraisal guidance 187. 2010:4–5
   Google Scholar
• Stidham RW, Higgins PD. Value of mucosal assessment and biomarkers in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010;4:285–91.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van AG, Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295–301.
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van AG, Caenepeel P, Vergauwe P, De VM, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463–8.
   PubMed Web of Science ®Google Scholar
• Florholmen J, Fries W. Candidate mucosal and surrogate biomarkers of inflammatory bowel disease in the era of new technology. Scand J Gastroenterol 2011;46:1407–17.
   PubMed Web of Science ®Google Scholar